drugset / Trial / NCT02504476

Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective

NCT02504476 ↗

Phase 1 Completed 52 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.

Timeline

Start
2015-08
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 581 Unknown — Oral
Subject Midazolam Small molecule — —

Indications